Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2016 / N 2

Сравнительная характеристика кардиоваскулярной безопасности сахароснижающих препаратов
С.А. Потапова, Е.В. Гончарова, Н.А. Петунина

1. IDF Diabetes Atlas – Seventh Edition, 2015. Online version of IDF Diabetes Atlas. Доступно по: www.diabetesatlas.org Ссылка активна на 29.07.2016.
2. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Клинические рекомендации. Сахарный диабет 2015; 18(1S): 1–112.
3. FDA. Guidance for industry: diabetes mellitus–evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. Доступно по: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Ссылка активна на 29.07.2016.
4. Gore M.O., McGuire D.K. The 10-year posttrial follow-up of United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context. Diab Vasc Dis Res 2009; 6: 53–55.
5. Ren J., Dominguez L.J., Sowers J.R., Davidoff A.J. Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Са2+ transients in adult rat ventricular myocytes. Diabetes 1999; 48(10): 2059–2065.
6. Selvin E., Bolen S., Yeh H.C., Wiley C., Wilson L.M., Marinopoulos S.S., Feldman L., Vassy J., Wilson R., Bass E.B., Brancati F.L. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168(19): 2070–2080.
7. Saenz A., Fernandez-Esteban I., Mataix A., Ausejo M., Roque M., Moher D. Metformin monotherapy for diabetes Mellitus. Cochrane Database Syst Rev 2005; (3): CD002966.
8. Evans J.M., Ogston S.A., Emslie-Smith A., Morris A. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulphonylureas and metformin. Diabetologia 2006; 49: 930–936.
9. Johnson J.A., Majumdar S.R., Simpson S.H., Toth E.L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244–2248.
10. Johnson J.A., Simpson S.H., Toth E.L., Majumdar S.R. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 2005; 22: 497–502.
11. Kao J., Tobis J., McClelland R.L., Heaton M.R., Davis B.R., Holmes D.R. Jr., Currier J.W.; Investigators in the Prevention of Restenosis With Tranilast and Its Outcomes Trial. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004; 93: 1347–1350.
12. Fisman E., Tenenbaum A., Boyko V., Benderly M., Adler Y., Friedensohn A., Kohanovski M., Rotzak R., Schneider H., Behar S., Motro M. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001; 24: 151–158.
13. Inzucchi S., Masoudi F., Wang Y., Kosiborod M., Foody J.M., Setaro J.F., Havranek E.P., Krumholz H.M. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction. Diabetes Care 2005; 28: 1680–1689.
14. Eurich D.T., Majumdar S.R., McAlister F.A., Tsuyuki R.T., Johnson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345–2351.
15. Masoudi F.A., Inzucchi S.E., Wang Y., Havranek E.P., Foody J.M., Krumholz H.M. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583–590.
16. Лапина Ю.В., Нарусов О.Ю., Мареев В.Ю., Болотина М.Г., Шестакова М.В., Масенко В.П., Литонова Г.Н., Арзамасцева Н.Е., Бакланова Н.А., Беленков Ю.Н. Эффективность и безопасность применения метформина у больных c хронической сердечной недостаточностью и сахарным диабетом 2 типа. Результаты исследования РЭМБО – СД ХСН (Рациональная Эффективная Многокомпонентная терапия в Борьбе с Сахарным Диабетом 2 типа). Кардиология 2008; (3): 58–68.
17. Aguilar D., Wenyaw Chan W., Bozkurt B., Ramasubbu K., Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 2011; 4: 53–58.
18. Lyons M.R., Peterson L.R., McGill J.B., Herrero P., Coggan A.R., Saeed I.M., Recklein C., Schechtman K.B., Gropler R.J. Impact of sex on the heart's metabolic and functional responses to diabetic therapies. Am J Physiol Heart Circ Physiol 2013; 305(11): H1584–1591.
19. Elrick H., Stimmler L., Hlad C., Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076–1082.
20. Herman G.A., Bergman A., Yi B., Kipnes M.; Sitagliptin Study 012 Group. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006; 22: 1939–1947.
21. Berndt-Zipfel C., Michelson G., Dworak M., Mitry M., Löffler A., Pfützner A., Forst T. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus–results from an exploratory study. Cardiovasc Diabetol 2013; 12: 59.
22. He Y.L., Sabo R., Picard F., Wang Y., Herron J., Ligueros-Saylan M., Dole W.P. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin 2009; 25: 1265–1272.
23. Mistry G.C., Bergman A.J., Zheng W., Hreniuk D., Zinny M.A., Gottesdiener K.M., Wagner J.A., Herman G.A., Ruddy M. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol 2008; 66: 36–42.
24. Mistry G.C., Bergman A.J., Luo W.L., Cilissen C., Haazen W., Davies M.J., Gottesdiener K.M., Wagner J.A., Herman G.A. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol 2007; 47: 159–164.
25. Karim A., Laurent A., Munsaka M., Wann E., Fleck P., Mekki Q. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol 2009; 49: 1210–1219.
26. Graefe-Mody U., Huettner S., Stähle H., Ring A., Dugi K.A. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther 2010; 48: 367–374.
27. Wei Y., Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptideI: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 219–224.
28. Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., Stolarski C., Shen Y.T., Shannon R.P. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110: 955–961.
29. Nikolaidis L.A., Doverspike A., Hentosz T., Zourelias L., Shen Y.T., Elahi D., Shannon R.P. Glucagon-like peptide-1 limits myocardial stun¬ning following brief coronary occlusion and rep¬erfusion in conscious canines. J Pharmacol Exp Ther 2005; 312: 303–308.
30. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54: 146–151.
31. Gomez N., Touihri K., Matheeussen V., Mendes Da Costa A., Mahmoudabady M., Mathieu M., Baerts L., Peace A., Lybaert P., Scharpé S., De Meester I., Bartunek J., Vanderheyden M., Mc Entee K. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail 2012; 14(1): 14–21.
32. Read P.A., Khan F.Z., Heck P.M., Hoole S.P., Dutka D.P. DPP-4 inhi¬bition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coro¬nary artery disease. Circ Cardiovasc Imaging 2010; 3(2): 195–201.
33. Theiss H.D., Brenner C., Engelmann M.G., Zaruba M.M., Huber B., Henschel V., Mansmann U., Wintersperger B., Reiser M., Steinbeck G., Franz W.M. Safety and efficacy of SITAgliptin plus GRanulocyte¬colony-stimulating factor in patients suffering from acute myocardial infarction (SITAGRAMI¬Trial)-Rationale, design and first interim analy¬sis. Int J Cardiol 2010; 145(2): 282–284.
34. Mistry G.C., Maes A.L., Lasseter K.C., Davies M.J., Gottesdiener K.M., Wagner J.A., Herman G.A. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008; 48: 592–598.
35. Green J.B., Bethel M.A., Armstrong P.W., Buse J.B., Engel S.S., Garg J., Josse R., Kaufman K.D., Koglin J., Korn S., Lachin J.M., McGuire D.K., Pencina M.J., Standl E., Stein P.P., Suryawanshi S., Van de Werf F., Peterson E.D., Holman R.R.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232–242.
36. Engel S.S., Golm G.T., Shapiro D., Davies M.J., Kaufman K.D., Goldstein B.J. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013; 12: 3.
37. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon- like pep- tide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340–2350.
38. Nathewani A., Lebault A., Byiers S., Gimpelewicz C., Chang I.H. Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for type 2 diabetes. Program and abstracts of the American Diabetes Association 66th Scientific Sessions. June 9–13, 2006. Washington, DC 2006; 474p.
39. Diess D., Bosi E., Riveline J.P., Battelino T., Bosi E., Tubiana-Rufi N., Kerr D., Phillip M. Improved glycemic control in poorly controlled patients with type 1diabetes using real-time continuous glucose monitoring. Diabetes Care 2006; 29: 2730–2732.
40. Matikainen N., Mänttäri S., Schweizer A., Ulvestad A., Mills D., Dunning B.E., Foley J.E., Taskinen M.R. Vildagliptin therapy reduces postprandial intestinal triglyceride rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 9: 2049–2057.
41. Ligueros-Saylan M., Schweizer A., Dickinson S., Kothny W. Vildagliptin therapy is not associated with an increased risk of pancreatitis. EASD Poster presentation, 2009.
42. He Y.-L., Sabo R., Riviere G.J., Sunkara G., Leon S., Ligueros-Saylan M., Rosenberg M., Dole W.P., Howard D. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007; 23: 1131–1138.
43. Ayalasomayajula S.P., Dole K., He Y.L., Ligueros-Saylan M., Wang Y., Campestrini J., Humbert H., Sunkara G. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 2007; 23 (12): 2913–2920.
44. Петунина Н.А., Трухина Л.В., Гончарова Е.В. Роль вилдаглиптина в оптимизации гликемического контроля. Справочник поликлинического врача 2012; (9): 46–49.
45. Аметов А.С., Кулиджанян Н.К., Шурупова Т.А., Трифонова Т.А., Анциферов М.Б. Влияние ингибиторов дипептидилпептидазы-4 на функциональное состояние миокарда у больных сахарным диабетом 2 типа. Фарматека 2012; (10): 79–86.
46. McInnes G., Evans M., Del Prato S., Stumvoll M., Schweizer A., Lukashevich V., Shao Q., Kothny W. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17000 patients. Diabetes Obes Metab 2015; 17(11): 1085–1092.
47. Hong A.R., Lee J., Ku E.J., Hwangbo Y., Kim K.M., Moon J.H., Choi S.H., Jang H.C., Lim S. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): a randomized trial. Diabetes Res Clin Pract 2015; 109: 141–148.
48. Forst T., Koch C., Dworak M. Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study. Curr Med Res Opin 2015; 31: 1079–1084.
49. Ishii M., Shibata R., Kondo K., Kambara T., Shimizu Y., Tanigawa T., Bando Y.K., Nishimura M., Ouchi N., Murohara T. Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism. J Biol Chem 2014; 289: 27235–27245.
50. Miyoshi T., Nakamura K., Yoshida M., Miura D., Oe H., Akagi S., Sugiyama H., Akazawa K., Yonezawa T., Wada J., Ito H. Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic betaadrenergic stimulation in rats. Cardiovasc Diabetol 2014; 13: 43.
51. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., Ohman P., Frederich R., Wiviott S.D., Hoffman E.B., Cavender M.A., Udell J.A., Desai N.R., Mosenzon O., McGuire D.K., Ray K.K., Leiter L.A., Raz I.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317–1326.
52. Leiter L.A., Teoh H., Braunwald E., Mosenzon O., Cahn A., Kumar K.M., Smahelova A., Hirshberg B., Stahre C., Frederich R., Bonnici F., Scirica B.M., Bhatt D.L., Raz I., SAVOR-TIMI 53 Steering Committee and Investigators. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care 2015; 38: 1145–1153.
53. Iqbal N., Parker A., Frederich R., Donovan M., Hirshberg B. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol 2014; 13: 33.
54. Eurich D.T., Weir D.L., Simpson S.H., Senthilselvan A., McAlister F.A. Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study. Diabet Med 2015. 33(5): 621–630.
55. Scirica B.M., Braunwald E., Raz I., Cavender M.A., Morrow D.A., Jarolim P., Udell J.A., Mosenzon O., Im K., Umez-Eronini A.A., Pollack P.S., Hirshberg B., Frederich R., Lewis B.S., McGuire D.K., Davidson J., Steg P.G., Bhatt D.L., SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014; 130: 1579–1588.
56. Wu S., Hopper I., Skiba M., Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther 2014; 32(4): 147–158.
57. Gallwitz B. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes. Diabetes Metab Syndr Obes Targets Ther 2013; 6: 1–9.
58. Guedes E.P., Hohl A., de Melo T.G., Lauand F. Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment. Diabetol Metab Syndr 2013; 5: 25.
59. Retlich S., Duval V., Graefe-Mody U., Friedrich C., Patel S., Jaehde U., Staab A. Population pharmacokinetics and pharmacodynamics of Linagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2015; 54: 737–750.
60. Rosenstock J., Marx N., Neubacher D., Seck T., Patel S., Woerle H.J., Johansen O.E. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol 2015; 14: 57.
61. Rosenstock J., Marx N., Kahn S.E., Zinman B., Kastelein J.J., Lachin J.M., Bluhmki E., Patel S., Johansen O.E., Woerle H.J. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013; 10: 289–301.
62. Marx N., Rosenstock J., Kahn S.E., Zinman B., Kastelein J.J., Lachin J.M., Espeland M.A., Bluhmki E., Mattheus M., Ryckaert B., Patel S., Johansen O.E., Woerle H.J. Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes: CAROLINA. Diab Vasc Dis Res 2015; 12: 164–174.
63. FDA doctor. Clinical Trial CARMELINA Study with Linagliptin in Patients with Type II Diabetes. 2015. http://fdadoctor.com/clinical-trial-carmelina-study-with-linagliptin-in-patients-with-type-ii-diabetes/ Accessed 01.08.2016.
64. Groop P.-H., Cooper M.E., Perkovic V., Emser A., Woerle H.-J., von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013; 36: 3460–3468.
65. Von Eynatten M., Gong Y., Emser A., Woerle H.-J. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovasc Diabetol 2013; 12: 60.
66. McGill J.B., Sloan L., Newman J., Patel S., Sauce C., von Eynatten M., Woerle H.J. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013; 36: 237–244.
67. Koibuchi N., Hasegawa Y., Katayama T., Toyama K., Uekawa K., Sueta D., Kusaka H., Ma M., Nakagawa T., Lin B., Kim-Mitsuyama S. DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovasc Diabetol 2014; 13: 157.
68. Terawaki Y., Nomiyama T., Kawanami T., Hamaguchi Y., Takahashi H., Tanaka T., Murase K., Nagaishi R., Tanabe M., Yanase T. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol 2014; 13: 154.
69. Covington P., Christopher R., Davenport M., Fleck P., Karim A. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-mind, placebocontrolled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008; 30: 499–512.
70. Ndefo U.A., Okoli O., Erowele G. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. Am J Health Syst Pharm 2014; 71: 103–109.
71. Jarvis C.I., Cabrera A., Charron D. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Ann Pharmacother 2013; 47: 1532–1539.
72. White W.B., Bakris G.L., Bergenstal R.M., Cannon C.P., Cushman W.C., Fleck P., Heller S., Mehta C., Nissen S.E., Perez A., Wilson C., Zannad F. Examination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J 2011; 162: 620–626.
73. Петунина Н.А, Терехова А.Л. Алоглиптин – новый представитель класса ингибиторов ДПП-4. Ожирение и метаболизм 2014; (4): 25–31.
74. Pratley R.E. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 2009; 10: 503–512.
75. Scott L.J. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010; 70: 2051–2072.
76. Zannad F., Cannon C.P., Cushman W.C., Bakris G.L., Menon V., Perez A.T., Fleck P.R., Mehta C.R., Kupfer S., Wilson C., Lam H., White W.B., EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 385: 2067–2076.
77. Keating G.M. Alogliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs 2015; 75: 777–796.
78. Kaku K., Katou M., Igeta M., Ohira T., Sano H. Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group, comparative study. Diabetes Obes Metab 2015; 17(12): 1198–1201.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]